Indication
Adrenal cortex carcinoma
Adrenal cortex carcinoma, commonly referred to as adrenocortical carcinoma, is a rare and aggressive endocrine malignancy originating in the outer layer of the adrenal gland. Read more about Adrenal cortex carcinoma
4 drugs 4 manufacturers
Drugs that treat it
Common Adrenal cortex carcinoma therapies.
LYSODREN (mitotane)
LYSODREN (mitotane)
LYSODREN (mitotane)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonAdrenal cortex carcinoma, commonly referred to as adrenocortical carcinoma, is a rare and aggressive endocrine malignancy originating in the outer layer of the adrenal gland.
It can affect both pediatric and adult populations, often exhibiting a bimodal age distribution peaking in early childhood and again in the fourth to fifth decades of life.
Pathophysiologically, the tumor arises from steroidogenic adrenocortical cells and may present as nonfunctional or functional.
Functional tumors hypersecrete adrenal steroids—most commonly cortisol, androgens, or aldosterone—leading to endocrine syndromes such as Cushing syndrome, virilization, or refractory hypertension.
Nonfunctional variants typically manifest late with abdominal mass effect, localized pain, or incidental retroperitoneal imaging findings, and carry a pronounced risk of local invasion and distant metastasis.
- clevelandclinic.org
Adrenal cortex carcinoma, commonly referred to as adrenocortical carcinoma, is a rare and aggressive endocrine malignancy originating in the outer layer of the adrenal gland
- nih.gov
Adrenal cortex carcinoma, commonly referred to as adrenocortical carcinoma, is a rare and aggressive endocrine malignancy originating in the outer layer of the adrenal gland It can affect both pediatric and adult populations, often exhibiting a bimodal age distribution peaking in early childhood and again in the fourth to fifth decades of life Pathophysiologically, the tumor arises from steroidogenic adrenocortical cells and may present as nonfunctional or functional Functional tumors hypersecre...
- cancer.gov
Pathophysiologically, the tumor arises from steroidogenic adrenocortical cells and may present as nonfunctional or functional Functional tumors hypersecrete adrenal steroids—most commonly cortisol, androgens, or aldosterone—leading to endocrine syndromes such as Cushing syndrome, virilization, or refractory hypertension
- nih.gov
Functional tumors hypersecrete adrenal steroids—most commonly cortisol, androgens, or aldosterone—leading to endocrine syndromes such as Cushing syndrome, virilization, or refractory hypertension Nonfunctional variants typically manifest late with abdominal mass effect, localized pain, or incidental retroperitoneal imaging findings, and carry a pronounced risk of local invasion and distant metastasis
- nih.gov
Nonfunctional variants typically manifest late with abdominal mass effect, localized pain, or incidental retroperitoneal imaging findings, and carry a pronounced risk of local invasion and distant metastasis
Personalize your experience
Follow Adrenal cortex carcinoma and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.